Loading patent…
AssigneeGemphire Therapeutics Inc.
InventorsCarmen Daniela ONICIU, Otto Joseph GEOFFROY
Estimating the term…
The present disclosure provides a process for the preparation of compounds of formula (III), compounds of formula (V), and corresponding salts of formula (IV). The compounds made by the methods and processes of the invention are particularly useful for administration in humans and animals.
A process for preparing a compound of formula (III):
A process for preparing 6,6′-oxy-bis(2,2-dimethyl-4-hexanoic acid):
A process for preparing crystalline 6,6′-oxybis(2,2-dimethyl-4-hexanoic acid) calcium:
A process for preparing a compound of formula (48):
A process for preparing a compound of formula (48):
A process for preparing a compound of formula (45):
Dependencies are inferred from the claim text.
Drawings are temporarily unavailable. Open the PDF at USPTO
From the US filing history. Foreign family members aren’t listed.
Backward citations are indexed for grants only.
By modifying the acid moiety of the ester, such modification not being an introduction of an ester group: by introduction of functional groups…
Drugs for disorders of the metabolism: antihyperlipidemics
For glucose homeostasis: for hyperglycaemia, e.g. antidiabetics
Drugs for disorders of the cardiovascular system: antihypertensives
Term end not estimated
α,ω-Dicarboxylic acid-terminated dialkane ethers have activity in lowering several plasma lipids, including Lp(a), triglycerides, VLDL-cholesterol, and LDL-cholesterol, both in animals and in humans. See U.S. Pub. No. 2010/0256209. The compounds also are known to increase insulin sensitivity. See U.S. Pub. No. 2010/0256209. In particular, 6,6′-oxy-bis(2,2-dimethyl-4-hexanoic acid) (also known as 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid), whose USAN name is gemcabene, and its calcium salt (gemcabene calcium) have been intensively studied in multiple clinical trials as a lipid lowering agent for the treatment of patients with low high-density lipoprotein (HDL) and high low density lipoprotein (LDL). See Bays, H. E., et al., Amer. J Cardiology, 2003, 92, 538-543. Gemcabene has been clinically tested as an anti-hypertensive and anti-diabetic agent in addition to the lipid lowering activity.
A synthetic method for the preparation of 6,6′-oxybis(2,2-dimethyl-4-hexanoic acid) and other α,ω-dicarboxylic acid-terminated dialkane ethers is described by Bisgaier, C. L. et al. in U.S. Pat. No. 5,648,387, which is incorporated herein by reference in its entirety. In addition, preparation and characterization of alcohol and water solvates of 6,6′-oxybis(2,2-dimethyl-4-hexanoic acid) calcium (gemcabene calcium), for the treatment of dyslipidemia, vascular disease, and diabetes are disclosed in U.S. Pat. No. 6,861,555, which is incorporated herein by reference in its entirety. Zhang, Y et al. also report a small scale synthesis of C-14- and tritiated-gemcabene congeners in J Label Compd Radiopharm 2007, 50, 602-604.
The previously disclosed syntheses raise a number of safety and environmental concerns when replicated on a scale larger than 1 kg. Thus, a need remains for safe and environmentally friendly processes for preparing α,ω-dicarboxylic acid-terminated dialkane ethers on a large scale.
The following abbreviations and terms have the indicated meanings throughout:
Abbreviation Meaning ° C. Degrees Celsius DMF Dimethylformamide DMSO Dimethyl Sulfoxide Et Ethyl Eq Equivalent HDL High-Density Lipoprotein Hr Hour LDA Lithium Diisopropylamide LDL Low-Density Lipoprotein Lp(a) Lipoprotein (a) M Molar
Abbreviation Meaning Min Minute RT Room Temperature VLDL Very Low-Density Lipoprotein